Maryland's Accelovance is stepping up its clinical research capabilities, buying Radiant Development, the CRO arm of Radiant Research.
Accelovance is keeping the financial particulars to itself, but the company says adding Radiant's services will expand its reach into new therapeutic areas. Accelovance has long specialized in vaccine, infectious disease and oncology research, but snatching up Radiant will give it capabilities in cardiovascular, dermatology and medical device studies, among other areas.
"We are thrilled to have 100% of the Radiant team led by Vita Lanoce as part of our company," Accelovance CEO Stephen Trevisan said in a statement. "Core values focused on meeting our client needs, open communication and relationships built on honesty and trust are important similarities between our organizations."
The buyout gives Accelovance new locations in Illinois, Florida and North Carolina, plus Radiant's established partnerships in Europe and Asia. From here on, Radiant Development will operate as a division of Accelovance, handling project management, regulatory consulting, safety testing and statistical services, the company said.
Radiant Research, bought by Clinical Research Advantage in November, retains its trial-management business, and Accelovance will maintain a preferred partner relationship with the company.
- read Accelovance's announcement